test

The agency previously authorised boosters of the Pfizer Inc PFE.N Covid-19 vaccine developed with German partner BioNTech SE BNTX.O at least six months after the first round of shots to increase protection for people aged 65 and older, those at risk of severe disease and those who are exposed to the virus through their work. Last week, an advisory panel to the FDA voted to recommend a third round of shots of the Moderna vaccine for the same groups.